This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
ResMed (RMD) Surpasses Q4 Earnings and Revenue Estimates
by Zacks Equity Research
ResMed (RMD) delivered earnings and revenue surprises of +3.66% and +1.87%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Implied Volatility Surging for Owens & Minor Stock Options
by Zacks Equity Research
Investors need to pay close attention to OMI stock based on the movements in the options market lately.
Owens & Minor (OMI) Q1 Earnings Top Estimates
by Zacks Equity Research
Owens & Minor (OMI) delivered earnings and revenue surprises of 15% and 1.43%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?
Are Options Traders Betting on a Big Move in Owens & Minor (OMI) Stock?
by Zacks Equity Research
Investors need to pay close attention to Owens & Minor (OMI) stock based on the movements in the options market lately.
Owens & Minor Shares Surge 39% on Earnings Beat and Growth Plans
by Zacks Equity Research
OMI's shares witnessed a massive uptick after the company posted stronger-than-expected Q4 earnings. Its strategic focus on Patient Direct and the Rotech acquisition indicates long-term shareholder value.
Owens & Minor (OMI) Tops Q4 Earnings and Revenue Estimates
by Zacks Equity Research
Owens & Minor (OMI) delivered earnings and revenue surprises of 3.77% and 0.65%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?
Owens & Minor (OMI) Expected to Beat Earnings Estimates: Should You Buy?
by Zacks Equity Research
Owens & Minor (OMI) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Will Owens & Minor (OMI) Beat Estimates Again in Its Next Earnings Report?
by Zacks Equity Research
Owens & Minor (OMI) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Implied Volatility Surging for Owens & Minor (OMI) Stock Options
by Zacks Equity Research
Investors need to pay close attention to Owens & Minor (OMI) stock based on the movements in the options market lately.
Owens & Minor (OMI) Q3 Earnings and Revenues Top Estimates
by Zacks Equity Research
Owens & Minor (OMI) delivered earnings and revenue surprises of 5% and 1.25%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?
LeMaitre Vascular (LMAT) Surpasses Q3 Earnings and Revenue Estimates
by Zacks Equity Research
LeMaitre (LMAT) delivered earnings and revenue surprises of 11.36% and 2.17%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?
Envista (NVST) Q3 Earnings and Revenues Beat Estimates
by Zacks Equity Research
Envista (NVST) delivered earnings and revenue surprises of 33.33% and 1.47%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?
Owens & Minor Stock to Gain From New Collaboration With Google Cloud
by Zacks Equity Research
OMI announces partnership with Google Cloud to enhance existing QSight capabilities.
What's in Store for Cardinal Health (CAH) in Q4 Earnings?
by Zacks Equity Research
Cardinal Health's (CAH) fourth-quarter fiscal 2024 results are expected to reflect solid performance in the Pharmaceutical and Specialty Solutions segment.
Should You Buy, Sell or Hold McKesson (MCK) Before Q1 Earnings?
by Zacks Equity Research
McKesson's (MCK) first-quarter fiscal 2025 results are likely to reflect the solid display by the U.S. Pharmaceutical and Specialty Solutions segment, driven by higher prescription volume.
5 Stocks Loved by Brokers Worth Watching Currently
by Maharathi Basu
Investors would do well to monitor stocks like ADTRAN (ADTN), Bread Financial (BFH), Owens & Minor (OMI), Bally's Corporation (BALY) and AMC Networks (AMCX) for high returns.
Baxter (BAX) to Report Q2 Earnings: What's in the Cards?
by Zacks Equity Research
Baxter's (BAX) second-quarter results are likely to benefit from positive pricing impact and new product launches. However, supply-chain issues are likely to have raised expenses in the quarter.
Owens & Minor (OMI) Q2 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
Owens & Minor (OMI) delivered earnings and revenue surprises of 9.09% and 0.79%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
BellRing Brands (BRBR) Earnings Expected to Grow: Should You Buy?
by Zacks Equity Research
BellRing Brands (BRBR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Can RadNet's (RDNT) Service Fee Revenues Help Lift Q2 Earnings?
by Zacks Equity Research
RadNet's (RDNT) Imaging Center segment is likely to have gained from the increased reimbursement from commercial and capitated payors and strong procedure volumes in the second quarter of 2024.
Will Owens & Minor (OMI) Beat Estimates Again in Its Next Earnings Report?
by Zacks Equity Research
Owens & Minor (OMI) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Owens & Minor (OMI) Earnings Expected to Grow: Should You Buy?
by Zacks Equity Research
Owens & Minor (OMI) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Wall Street Analysts Believe Owens & Minor (OMI) Could Rally 29.48%: Here's is How to Trade
by Zacks Equity Research
The consensus price target hints at a 29.5% upside potential for Owens & Minor (OMI). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Owens & Minor (OMI) Stock Jumps 7.6%: Will It Continue to Soar?
by Zacks Equity Research
Owens & Minor (OMI) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
biote Corp. (BTMD) Surges 10.4%: Is This an Indication of Further Gains?
by Zacks Equity Research
biote Corp. (BTMD) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term.